Cargando…

NMR spectroscopy of HIV-1 gp120 outer domain

Detalles Bibliográficos
Autores principales:	Sastry, M, Xu, L, Bhattacharya, S, Nabel, GJ, Bewley, CA, Kwong, PD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441272/ http://dx.doi.org/10.1186/1742-4690-9-S2-P20

Ejemplares similares

Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy
por: Sastry, Mallika, et al.
Publicado: (2011)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

P04-38. Crystal structure of gp120 in complex with the CD4-binding-site antibody b13 suggests precise targeting is needed for neutralization
por: Zhou, T, et al.
Publicado: (2009)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Eliciting neutralizing antibodies with gp120 outer domain
por: Qin, Y, et al.
Publicado: (2012)

Rate and affinity binding constants determined by SPR spectroscopy reveal differential antigenicity of HIV gp120 and gp140
por: Gearhart, TL, et al.
Publicado: (2012)

Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120
por: Zhou, T, et al.
Publicado: (2012)

P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection
por: Pegu, A, et al.
Publicado: (2009)

Immunogenicity of the outer domain of a HIV-1 clade C gp120
por: Chen, Hongying, et al.
Publicado: (2007)

Nitric oxide protects against HIV gp120 endothelial injury
por: Fiorucci, S, et al.
Publicado: (2010)

Antigen processing sites in gp120 are conserved across HIV virus clades
por: Yu, B, et al.
Publicado: (2012)

Length variation in HIV-1 gp120 as the product of DNA misalignment mechanism
por: Guglietta, Silvia, et al.
Publicado: (2010)

Differential glycosylation of envelope gp120 affects reactivity with HIV-1 specific antibodies
por: Czernekova, Lydie, et al.
Publicado: (2014)

Structural Dynamics of HIV-1 Envelope Gp120 Outer Domain with V3 Loop
por: Yokoyama, Masaru, et al.
Publicado: (2012)

Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design
por: Hu, Duoyi, et al.
Publicado: (2017)

Analysis of HIV-1 gp120 quasispecies suggests high prevalence of intra-subtype recombination
por: Kiwelu, IE, et al.
Publicado: (2012)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and co-receptor binding sites of HIV-1 gp120
por: Matz, J, et al.
Publicado: (2012)

Conformation-dependent recognition of HIV Gp120 by DARPins provides novel possibilities to develop distinct HIV entry inhibitors
por: Mann, AM, et al.
Publicado: (2012)

Virus-like particles highly expressing DC-SIGN concentrate trimeric HIV-envelope proteins with noncovalently linked immunoreactive gp120 and gp41
por: Vyas, GN
Publicado: (2012)

P09-01. Mutation of the gp120 alpha2 helix in early subtype C HIV-1 infection fails to alter neutralization sensitivity or efficiency of in vitro replication
por: Murphy, MK, et al.
Publicado: (2009)

HIV-1 subtype C primary isolates exhibit high sensitivity to an anti-gp120 RNA aptamer
por: Mufhandu, HT, et al.
Publicado: (2012)

HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells
por: Chung, NP, et al.
Publicado: (2012)

Rational modification of an HIV-1 gp120 results in enhanced neutralization breadth when used as a DNA prime
por: Wallace, A, et al.
Publicado: (2012)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
por: Yu, B, et al.
Publicado: (2012)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

P04-54 LB. Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals
por: Gnanakaran, G, et al.
Publicado: (2009)

P05-08. Eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein gp120: A strategy
por: Kelker, HC, et al.
Publicado: (2009)

The C5 region of HIV-1 gp120 binds specific
por: Dalgleish, A, et al.
Publicado: (2006)

Structural definition of a conserved neutralization epitope on HIV-1 gp120
por: Zhou, Tongqing, et al.
Publicado: (2007)

Anti-CD4-gp120 complex antibodies in long-term non-progressors HIV-1 positive patients: a role in slowing disease progression?
por: Burastero, Samuele, et al.
Publicado: (2006)

Structural comparison of somatically related PG9 and PG16 in complex with their epitope reveals differences in glycan recognition
por: Pancera, M, et al.
Publicado: (2012)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

P04-48. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after gp120 protein vaccination or chronic HIV-1 infection
por: Bonsignori, M, et al.
Publicado: (2009)

Simple, scalable and robust purification of two HIV-1 subtype C gp120 monomer subunit antigens for phase II clinical trial in Republic of South Africa
por: Wen, Y, et al.
Publicado: (2012)

P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold
por: Totrov, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_aif546sqh0f7di0v0ccpog21fu